Augmenix Obtains $6,100,000 Series B Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    204 2nd Avenue Waltham, MA 02451
  • Company Description
    Augmenix™, Inc. is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Augmenix, Inc.’s initial product will be the first synthetic tissue spacer designed and indicated to reduce radiation exposure of normal tissues adjacent to prostate cancers. Augmenix’s vision is to address unmet patient needs following cancer radiotherapy in a variety of organ systems by developing first-of-a-kind therapeutic products based on proprietary in-situ formed hydrogel technology.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds will be used to conduct the clinical and commercial development of the SpaceOAR((TM)). System in Europe and the United States, as well as to develop other products in the Augmenix pipeline.
  • M&A Terms
  • Venture Investor
    Ascension Health Ventures
  • Venture Investor
    Versant Ventures
  • Venture Investor
    Pinnacle Ventures
  • Venture Investor
    Catalyst Health & Technology Partners

Trending on Xconomy